Skyrocketing Drug Prices

Friday June 1, 2018

Prescription drugs treat conditions and improve patient health. But when drug prices are too high, access to medicines becomes out of reach for far too many patients.

When the price of prescription drugs fits within a family’s budget, everyone is able to live and work at their healthiest. On the other hand, when people are unable to afford their medication, this negatively affects their health and their lives and exacts a heavy toll on society.

Why are patients paying more?

This crisis is fueled by the high launch prices of new brand biologics and year-over-year price increases of brand drugs that face no competition in the market for many years due to abuses of the patent system. A recent report shows the average annual price of specialty drugs has tripled over the last ten years from nearly $18,000 to more than $52,000 today.1

With brand-name drugs now accounting for 77 percent of all spending on prescription drugs, patients are experiencing higher pharmacy costs, higher premiums and higher deductibles as a result of high brand drug prices.2 Moreover, taxpayers are footing the bill as increased prescription drug spending drives up Medicare and Medicaid spending. The increasing cost of brand drugs is unsustainable.

What is the solution?

Increasing patient access to more affordable, FDA-approved generic and biosimilar medicines is a proven and tested solution to lowering prescription drug costs. When generic competition exists, prices are often 80-85 percent less than the brand drug,3 according to the FDA.

Biosimilars – which are affordable alternatives to expensive brand biologics, like Humira and Remicade– also are starting to come to market. The FDA has approved nine biosimilars but only three are available to patients to date. While the U.S. is still behind Europe in terms of patient access to biosimilars, the potential savings could reach $54 billion over the next ten years.4 Yet the FDA Commissioner has called out brand-name drug company abuses of the patent and regulatory system that attempt to sabotage the growth of biosimilars.

With increased access to generics and biosimilars, patients are less likely to abandon their prescriptions at the pharmacy counter. And with 90 percent of generic prescriptions available for less than $20 for patients with insurance, this means real savings to family budgets and healthier lives for all of us.5

Who is benefitting from the status quo?

While it seems as if the trade association for brand-name drug companies has launched a new public relations campaign pointing the finger at other stakeholders in the drug supply chain every week, and lawmakers in state capitals and in Congress seek solutions on drug prices, let’s remember who’s driving up the cost of prescription drugs and who benefits from these high prices.

When three out of every four dollars of the price is retained by brand-name drug companies, it’s those drug companies who benefit the most from high drug prices.6 And patients, without access to more affordable, FDA-approved generics or biosimilars, are stuck paying the bill.

It’s time to do something about sky-high prescription drug costs. Let’s increase competition, end patent abuse and work to bring drug prices back down to Earth.

Download The Infographic

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more

GRx+Biosims 2019

Join us in Bethesda, Maryland on November 4-6, 2019 for the premier scientific and regulatory event for the U.S. generics and biosimilars industries.

LEARN MORE

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER